UPCC 25417: A Randomized Phase 3 Study to | Clinical Research Studies Listing

UPCC 25417: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Recruiting

99 years or below

All

Phase 3

10 participants needed

1 Location

Brief description of study

Request for collaborative review: Sterling IRB serving as IRB of record.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Amyloidosis
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 827805

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

UPCC 25417: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Brief description of study

Eligibility of study

Find a site

Interested in the study